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Abstract
In the last years, the variety and consumption of cosmetics and personal care 
products (PCPs) have greatly increased, although the long-term adverse effects to low 
doses of chemicals used in their production and with proven hormone-mimicking 
properties have been still poorly addressed. Among these endocrine disrupting 
chemicals (EDCs), parabens, benzophenones, bisphenols, and phthalates are the 
most widely found in these products. Given the estrogenic-dependent nature of the 
endometrium, it has been hypothesized the potential contribution of these EDCs 
contained in cosmetics and PCPs in the risk of endometriosis. In this book chapter, 
we have summarized the current evidence supporting this hypothesis, highlight-
ing epidemiological, in vivo, and in vitro studies that have addressed the potential 
influence of parabens, benzophenones, bisphenols, and phthalates in the origin and 
progression of this chronic feminine disease.
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1. Introduction
The term “cosmetic” has its origin from the Greek term “kosme’tikos,” a noun 
to denote the art of beautifying the body [1]. Since ancient times, humans have 
searched for materials and developed many products to mainly enhance female 
beauty. Over the centuries, cosmetics have been developed and influenced by 
different ethnic traditions, from the times of the Pharaohs to the modern times [2]. 
Since then, physical appearance has been an inseparable part of daily human exis-
tence, improving their self-image and self-esteem. However, the esthetic concept of 
beauty has changed overtime, and beauty standards have been modified according 
to many factors such as social, ethnic, and religious belief influences [2]. Personal 
hygiene has been also part of human life since the ancient times. Traditionally 
related to hygiene habits during religious activities, the preparation of food, or the 
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prevention of diseases, hygiene practices have also greatly changed through the 
cultures and eras, from bathing facilities in the Roman period to modern synthetic 
products such as body lotions or hair tonics [3].
In the last years, the variety of cosmetics and personal care products (PCPs) 
have greatly increased (Table 1), in parallel to their manufacturing and consump-
tion volumes in developed and developing countries. For example, the consumption 
of cosmetics and perfumery in Spain has consecutively increased in the last years, 
reaching a total of 1280 million units sold of these products and 770 million units 
exported during 2018. To date, the USA is the leader in the consumption of cosmetics 
and perfumery, with an amount of 78.6 billion euros, followed by China (52 billion 
euros), Japan (32 billion euros), and Brazil (28 billion euros) [4]. Despite the cur-
rent beauty standards are not similar along cultures and ethnicities, it is acknowl-
edged that women have a greater use of cosmetics and personal care products 
(PCPs) when compared with men [5], and therefore, potential adverse effect may 
affect predominantly to this population.
Table 1 summarizes the main types of cosmetics and PCPs commonly used 
worldwide.
2. Endocrine disruptors in cosmetics and PCPs
2.1 What is an endocrine disruptor?
The World Health Organization defines an endocrine disrupting chemical 
(EDC) as an exogenous substance or mixture of substances that alter one or more 
functions of the endocrine system and consequently cause adverse effects on the 
health of an intact organism or its progeny [6].
The main characteristics of exposure to EDCs are as follows [7–10]:
• There is no safe dose of EDCs. They act at low concentrations and in combina-
tion with endogenous hormones, making it difficult to establish a threshold 
level of no effect.
• Exposure to EDCs during periods of special vulnerability of the individual’s 
development—pregnancy, lactation, puberty—causes damage with adverse 
effects throughout their lives and descendants.
Table 1. 
Most used cosmetics and personal care products.
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• The curves that relate the exposure doses to EDCs with the adverse effect are 
not linear. The response does not always increase in the same proportion as the 
exposure dose.
• In general terms, individuals are not exposed to a single type of EDC but to a 
mixture of EDCs. Therefore, the effects are difficult to predict given the pos-
sible synergistic, additive, or antagonistic actions between chemical residues 
(the cocktail effect).
• As a result of exposure to EDCs in a certain individual, consequences can 
be observed in subsequent generations, due to either genomic involvement 
or epigenetic mechanisms. There is great difficulty in establishing a causal 
association because the effects observed after exposure can occur after long 
latency periods.
2.2 Sources and routes of exposure to EDCs
EDCs are distributed in the environment due to their widespread use. 
Depending on their resistance to physical, chemical, and biological degradation 
as well as their degree of liposolubility, EDCs can be divided into “persistent 
EDCs” and “non-persistent EDCs.” In the case of persistent EDCs, low biode-
gradability, volatility, bioaccumulation in the trophic chain, and biomagnifica-
tion are its most outstanding characteristics [11]. Furthermore, they can be 
transmitted to the offspring through the mother during pregnancy and lactation 
[12]. Since the 1970s, most countries have banned or severely restricted the 
production, handling, and disposal of the majority of them due to consistent 
evidence of their adverse effects at doses traditionally considered safe [13, 14]. 
Despite this, global population is suspected to be primarily exposed to these 
pollutants through diet, given the bioaccumulation pattern of these chemicals in 
the food chain [14].
On the other hand, non-persistent EDCs are less liposoluble, and therefore, 
they are prone to be metabolized and excreted rapidly [15, 16]. In addition to 
a variety of pesticides such as glyphosate or permethrins, this group includes 
bisphenol-A (BPA) and its analogues, parabens (PBs) [methyl- (MeP), ethyl- 
(EtP), propyl- (PrP), and butyl-paraben (BuP)], phthalates, and benzophenones 
(BPs). Currently, there is diverse evidence showing the presence of numerous 
EDC families (mainly phthalates, bisphenols, parabens, and benzophenones) in 
cosmetic products and PCPs [17–20]. However, contrary to most persistent EDCs, 
international regulation of their production, handling, and disposal is limited to a 
reduction in the concentrations of some specific compounds for those cosmetics in 
the EU market (EU 1004/2014). Table 2 summarized the trade name, CAS num-
ber, and hormonal activity attributed to some of the most frequently used EDCs in 
cosmetics and PCPs.
Phthalates are used as a plasticizer in cosmetics and PCPs. The study carried 
out by Gao and Kannan [17] recently revealed that phthalates were found in >90% 
of the 77 feminine hygiene products analyzed. Mainly, they were found in all the 
tested pads, panty liners, tampons, and wipes. Furthermore, phthalates were also 
found in bactericidal creams and solutions, deodorant sprays, and powders. In 
another study, Guo and Kannan [18] showed that phthalates were also present in 
leave-on products, such as skin lotions, hair care products, perfumes, skin ton-
ers, deodorants, and creams. In this regard, detectable levels of phthalates were 
found in face creams, eyeliner creams, hand creams, sunscreens, lipsticks, and nail 
polish. These EDCs were also detected in products for dental hygiene and rinse-off 
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products (including body wash, shampoos, hair conditioners, face cleaners, and 
shaving gels).
In the case of the PB family, its main use in cosmetic products and PCPs is due 
to their antimicrobial properties [21]. It has been shown that the use of mixtures 
of paraben congeners allows the increase of their preservative capacity with the 
use of lower levels of each compounds [19]. Average daily application rates per 
women for face creams, hand or body lotions, facial cleansers, shampoos, and 
bath gel were 2.1, 8.7, 4.1, 12.8, and 14.5 g, respectively [22]. Yazar and Johnsson 
[20] carried out a study where they verified the composition of a series of 204 
cosmetic products, which included shampoos, hair conditioners, liquid soap, 
wipes from different brands, and stores. The results showed that at least 44% 
of the analyzed cosmetics contained at least one PB congener. The PB that was 
found in the highest proportion was MeP (41% of the products), followed by 
PrP (25%). In the study carried out by Gao and Kannan [17], it was found that 
all feminine hygiene products contained at least one PB, and both MeP and EtP 
were found in >80% of these compounds, mainly in wipes, creams, bactericide 
solutions, deodorant sprays, and powders. Moreover, it has been reported that 
PBs were detected in 40% of the dental hygiene products analyzed and 60% 
in other types of daily hygiene products. MeP and PrP were the most detected 
compounds (40% of the analyzed samples), followed by BuP (∼20%). The 
highest concentrations of MeP, EtP, PrP, and BuP ranged between 1040 and 
8200 μg/g, which represent approximately 0.1–0.8% per product by weight 
[18]. Another study carried out in China [19] found PBs in all the categories of 
PCPs analyzed. Almost all creams, lotions, and face cleaners contained MeP and 
PrP, with concentrations of MeP slightly higher than PrP (2830 and 1560 μg/g, 
respectively). Their presence was greater in creams and lotions than in shampoos 
and body soaps.
BPs are used as ultraviolet (UV) filters. As shown in the study carried out by 
Rastogi [23], 75 sunscreen products from Europe and the USA tested contained levels 
of up to three UV filters. A recent study [24] verified the presence of BP-1 and BP-3 in 
19.1% of their analyzed products (283 samples analyzed), especially in makeup 
products, which represented 45.2% of the products with the presence of BPs.
Trade name, CAS number and demonstrated hormonal activities.
Table 2. 
Most common endocrine disrupting chemicals in cosmetics and personal care products.
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In addition to these three families, the chemical composition of cosmetics and 
PCPs also contains many other compounds, although with a lower percentage of the 
presence in these products. Among them, bisphenols, camphenes, dimethicones, 
and oxycinnamates can be found. Within these minority families, bisphenols are the 
one that are usually found in the greatest presence in cosmetic products. The main 
use of BPA is the manufacture of epoxy resins, obtaining polycarbonate plastics, 
which have great mechanical and thermal stability, as well as very good transpar-
ency [25], while the main use of the families of camphenes, dimethicones, and 
oxycinnamates is that they are used as preservatives in the manufacture of PCPs 
[26, 27]. Nevertheless, the concentrations of these substances in cosmetics and 
PCPs have been poorly addressed.
Contrary to persistent EDCs that mainly reach body internal compartments 
through diet, the main route of human exposure to non-persistent EDCs released 
from cosmetics and PCPs is mainly the dermal route [28]. Therefore, these EDCs 
avoid the first-pass metabolism, enhancing the bioavailability and therefore the 
biological effect of the parent compounds [15]. In this regard, several studies have 
related to the use of cosmetics and PCPs and internal levels of PB and BPs. For 
example, it has been recently found that levels of some PB and BPs in menstrual 
blood are related to the use of cosmetics [29]. Moreover, urinary concentrations 
of PBs were related to the use of hair products, deodorants, face, and hand creams 
[30]. Similarly, Larsson et al. [31] found higher levels of PBs and phthalates among 
those women with higher use of hygiene products.
2.3 Mechanisms of action of EDCs
EDCs act at very different levels of complexity, interfering a variety of hor-
mone-signaling pathways. For instance, they can modify the circulating levels of 
hormones by acting on their synthesis, metabolism, or degradation. They can also 
reduce, increase, or interfere with the specific receptors for hormonal action and 
therefore affect the ability to respond to natural hormones [32]. In the particular 
case of EDCs that interfere in steroid hormone-related signaling pathways, the 
observed effects seem to be linked to the activation/blocking of nuclear receptors, 
which are the most common modes of action responsible for dose curves with non-
monotonic response in experimental studies [33]. In fact, many EDCs released from 
cosmetics and PCPs have been evidenced to exert estrogenic and antiandrogenic 
activities in both in vivo and in vitro studies [34–40] (see Table 2).
An increasing number of studies have also linked exposure to EDCs with epi-
genetic changes in humans [41, 42]. An unexposed individual may show epigenetic 
changes due to (1) altered ovum or sperm after EDC exposure or (2) in utero expo-
sure to EDCs. In this regard, it has been evidenced that fetal exposure to environ-
mental pollutants with endocrine disrupting properties such as mirex, chlordane, 
or p,p´-DDE can cause epigenetic changes with transgenerational effects [43, 44]. 
This is also the case of bisphenol-A (BPA), and PBs, with epigenetic changes after 
prenatal and adolescence exposures to these chemicals [45, 46].
Furthermore, inflammation and oxidative stress have also been recently pos-
tulated as possible mechanisms of action of EDCs [47–50]. In this regard, oxida-
tive stress, that is, the imbalance between the production of free radicals and the 
antioxidant capacity, has been shown to be enhanced after exposure to a variety of 
EDCs, including PBs and BPs [47, 49, 50]. For instance, human exposure to PB and 
BP has been linked to higher levels of lipid peroxidation [50, 51]. Moreover, local 
disruption of the antioxidant capacity has also been reported [47]. Although the 
underlying mechanisms are still poorly understood, it has been suggested that, at 
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least in part, EDCs might induce oxidative stress via estrogen receptor-α signal-
ing pathways [52]. Moreover, EDC exposure has also been evidenced to trigger an 
inflammatory microenvironment [50, 53]. With an intimate relationship, both oxi-
dative and inflammatory responses have also been suggested as crucial mechanisms 
beyond a variety of chronic diseases, as well as some gynecological conditions such 
as endometriosis [54, 55].
3. Potential adverse effects of EDC exposure
The consequences of exposure to EDCs seem to be different depending on age 
and gender (Table 3). In the case of men, EDC exposure is suspected to cause 
alterations in the development of the genitourinary system including cryptor-
chidism, testicular cancer, and infertility [56, 57]. Among women, the increase 
in hormone-dependent cancers (either breast or ovarian) [56] as well as uterine 
fibroids and endometriosis might also be related to inadvertent exposure to EDCs. 
Moreover, chronic conditions such as metabolic syndrome and its components 
(obesity, insulin resistance, hypertension, or dyslipidemia), neurobehavioral 
development disorders, and poor thyroid function are also on the list of possible 
effects of EDC exposure. In particular, in utero exposure to EDCs is believed to have 
consequences of such magnitude that they would hardly be suspected in studies of 
adult individuals. For example, in utero exposure to some EDCs has been linked 
to increased risk for breast cancer or endometriosis [58, 59]. This association gives 
maternal exposure some very particular peculiarities and places women of child-
bearing age in the limelight of most studies on endocrine disruption.
3.1 Use of cosmetics and PCPs and feminine diseases
Over the years and in parallel with the change in people’s habits and lifestyle, 
numerous evidence has revealed that cosmetics could cause a variety of disease 
conditions in humans. For instance, women are suspected to have a greater risk for 
some chronic conditions such as obesity and metabolic syndrome than men [60], 
and in addition to physiological differences between genders, the greater female 
consumption of cosmetics and PCPs might also underlie this enhanced risk. Moreover, 
the consumption of cosmetics and PCPs might also be beyond the development of 
female-specific diseases such as breast or ovarian cancer. In this regard, Darbre [61] 
Table 3. 
Some adverse effects of EDCs in humans.
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first alarmed scientific community about the potential effect of PCPs in breast cancer, 
suggesting that underarm cosmetic use might increase breast cancer. In fact, they 
detected a variety of EDCs including PBs in breast tumors, with higher concentrations 
in those samples from the axilla region, suggesting that their concentrations might 
be related to the application of deodorant products, body lotions, sprays, moistur-
izers, and sunscreen products in areas close to the human breast. However, current 
evidence on the relationship between cosmetic/PCP use and risk of cancer is not very 
conclusive. In this regard, in a case-control study comprised by 209 cases of breast 
cancer and 209 healthy controls, Linhart and Talasz [62] reported that the greater use 
of underarm cosmetic products was associated with increased risk of breast cancer. 
Contrary, a cohort study did not found any association between use of skincare 
products and risk of cancer of the breast and endometrium [63]. Another study 
carried out by McGrath [64] reported that those women with a higher use of antiper-
spirant products were diagnosed with breast cancer at an earlier age. Furthermore, 
it has been observed that long-term exposure to body care creams containing ethinyl 
estradiol may increase the risk of abnormal genital bleeding and breast cancer [65]. 
Interestingly, a case-report study found that synthetic hormones found in lotions used 
by the mother were present in very high concentrations in the hair of the girl [66].
However, the variety of products and differences in dosage, patterns of use, 
and individual susceptibility to specific product formulations pose great difficul-
ties to detect a potential effect of cosmetic and PCP habits on human adverse 
effects [36, 61, 67–69]. Thus, the use of internal burden of EDCs seems to better 
reflect the magnitude of cosmetic and PCP use, independently of the type of 
product used or the dose applied. In this regard, urinary levels of PBs have been 
related to greater risk for breast cancer [70]. Some studies have also addressed 
the potential association between exposure to PCP-released EDCs and the origin 
and development of other female diseases. In this regard, the presence of trace 
levels of PBs was found in endometrial tissue samples suspected of being related 
to an increased risk of endometrial carcinoma [71]. Levels of PrP were also related 
to diminished ovarian reserve in a prospective cohort study of the US women 
seeking fertility treatment [72]. Regarding the development of sex characteristics 
during puberty, a recent study observed associations between levels of PBs and 
earlier development of the breasts and the pubic hair in girls. Moreover, earlier 
menarche was also related to higher levels of PBs [73].
Regarding BPs, in vitro studies have shown that exposure to BPs in rats and 
mice has been related to feminized sexual behavior and increased uterine weight 
[39, 74]. Two in vivo studies have also demonstrated the disturbance caused by BP 
in ovarian tissue [75, 76]. Santamaría and Abud [75] found that exposure to BP-1 
and BP-3 disrupted early events in ovarian cells, such as germ cell development and 
disruption of crucial gene expression related to follicular assembly. Similarly, Shin 
and Go [76] reported the induction of BP-dependent metastasis in an in vivo model 
for ovarian cancer. Moreover, an epidemiological study has reported that urinary 
BP levels might be associated with blood pressure during pregnancy [77]. Similarly, 
higher BP levels were related to thyroid hormones and growth factors in pregnant 
women, as well as to reduced fetal growth [74].
Other hormonally active chemicals widely used in cosmetics are phthalates. 
Exposure to various congeners has been associated with the appearance of vari-
ous female diseases. Exposure to di-(2-ethylhexyl) phthalate has been linked to 
an increased risk of preterm delivery [78–80] and intrauterine growth restriction 
[81]. Furthermore, it has also been associated with reduced total oocyte yield and 
a reduced probability of achieving pregnancy and live birth [82]. Other phthal-
ate congeners, such as monoethyl phthalate and dibutyl phthalate, have also been 
linked to decreased fertility in women [79, 83].
Endometriosis
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Several investigations have also suggested the potential association between 
BPA exposure and adverse outcomes in women. For instance, it has been shown 
that elevated serum or urine BPA levels are associated with anovulation [84], lower 
antral follicle counts [85, 86], preterm birth [87], and infertility [88]. Moreover, 
increasing urinary BPA levels were associated with delayed menarche in ado-
lescent girls [89, 90]. Furthermore, higher BPA levels have been associated with 
an increased risk of developing polycystic ovary syndrome [84, 91–93], ovarian 
failure [94], infertility [95], and fibroids [96, 97]. Triclosan, widely present in 
soaps, detergents, and toothpaste, has also been related to decreased fertility [98], 
although the currently available evidence is scarce.
3.2 Associations between PCP- and cosmetic-released EDCs and endometriosis
As mentioned above, detectable levels of PBs and BPs have been detected in 
endometrial tissue and menstrual blood [29, 71]. Trace levels of intact PBs were 
predominantly detected in endometrial carcinoma tissues (23%) in contrast to 
normal endometrium samples (2%), and thus, authors suggested that they might 
be related to an increased risk of endometrial carcinoma [71]. On the other hand, 
several PBs and BPs have been detected in menstrual blood samples, a biological 
sample in intimate contact with the endometrium [29]. Moreover, these menstrual 
blood concentrations of PBs and BPs were related to the magnitude of use of creams 
and cosmetics, evidencing that these EDCs from cosmetics and PCPs are capable of 
reaching a wide variety of biological matrices and thus might orchestrate, or at least 
contribute, to the development and progression of multiple gynecological diseases 
such as endometrial cancer and endometriosis.
Concerning endometriosis, the origin of endometriosis still remains unclear. To 
date, although various theories have been postulated to give a possible explanation 
for the origin of endometriosis [99–105], none of them consistently explains the 
onset and progression of the disease in deeper stages. Currently, it is known that it 
is a multifactorial disease in which genetic, epigenetic, immunological, hormonal, 
and environmental factors are involved [106]. Due to the suspected increase in 
the number of cases in the last decades [107], it is suspected that, in addition to 
the increased awareness among doctors and patients, environmental risk factors 
are suspected to also contribute to the onset and progression of this disease. This 
environmental hypothesis of the origin of the disease is also reinforced due to the 
estrogen-dependent nature of this pathology [53, 108].
Despite the growing public concern about human risks derived from the use 
of PCPs and cosmetics, there is little evidence on their influence on endometriosis 
(Table 4). To our knowledge, only one study has investigated the relationship 
between EDCs released from sunscreens and endometriosis. Concentrations of 
2-hydroxy-4-methoxybenzophenone, 2,4-dihydroxybenzophenone, 2,2′-dihy-
droxy-4-methoxybenzophenone, 2,2′,4,4′-tetrahydroxybenzophenone, and 
4-hydroxi-benzophenone were analyzed in urine samples collected from 600 
women. The results obtained suggest that exposure to elevated levels of 2,4-dihy-
droxybenzophenone (BP-3) may be associated with a higher probability of a 
diagnosis of endometriosis [109]. As authors mentioned, these findings denoted an 
approximate 65% increase in the odds of an endometriosis diagnosis in women with 
the highest BP-3 concentration compared to women with lower concentrations.
Regarding BPA exposure, a recent meta-analysis revealed limited and contradic-
tory epidemiological evidence regarding the contribution of BPA in the risk for 
endometriosis [110]. Thus, despite few studies have reported an absence of associa-
tion between urinary levels of BPA and disease [111, 112], others reported increased 
risk for endometriosis [53, 113–115]. Even more, it has been recently suggested that 
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levels of oxidative stress might act as a mediation effect on the association between 
exposure to bisphenols and endometriosis risk [53]. Furthermore, exposure to BPA 
has not only been related to the onset of endometriosis, but it might be also involved 
in the progression of the disease [112, 114]. Moreover, these findings are supported 
by different experimental studies. In this sense, recent in vivo studies have evidenced 
in mouse models that exposure to bisphenols in adulthood was related to an increase 
in the growth of endometrial lesions and the number of atretic oocytes, the interrup-
tion of the ovarian steroidogenic pathway, an increase in periglandular fibrosis, and 
the upregulation of matrix remodeling enzymes [108, 116]. Another in vivo study 
revealed that prenatal exposure to BPA and other bisphenols caused a phenotype 
similar to endometriosis [117]. These experimental studies suggest that exposure to 
BPA could be related to the development and progression of endometriosis.
Table 4. 
Studies exploring associations between exposure to cosmetics- and PCPs-released EDCs and endometriosis.
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Other EDCs found in cosmetics and PCPs are phthalates. Several studies have 
explored the existing associations between exposure to these chemicals and endo-
metriosis, showing conflicting results. One of the very first investigations reported 
higher concentrations of phthalates in women with a confirmed diagnosis of 
endometriosis [118]. Similarly, two studies evidenced an increased risk of endo-
metriosis in women with higher levels of mono (2-ethylhexyl) phthalate [111, 119]. 
Conversely, few studies did not found any association between levels of urinary lev-
els of any phthalate congener and enhanced risk for endometriosis [112, 120–122].
Currently, there are no studies that have explored the possible contribution of 
other EDCs released from cosmetics and PCPs (such as parabens, oxycinnamates, 
camphenes, and dimethicones) and the risk of endometriosis. Moreover, the 
combined effect of EDCs released from these products on endometriosis has not 
been addressed yet.
4. Conclusions
To date, there is still very limited evidence on the potential role of EDCs released 
from cosmetics and PCPs on the origin and development of endometriosis. In 
general terms, in vitro, in vivo, and epidemiological evidence is consistent with the 
endocrine-disrupting hypothesis set out in this chapter, indicating that EDCs might 
be in the causal pathway that leads to endometriosis. Nevertheless, in all published 
studies, the particular effect of specific EDCs was measured, without taking into 
account the possible synergistic or antagonistic effect that these chemicals can 
exert when they are present in a mixture. Thus, because its diagnosis is difficult 
and its treatment is mainly symptomatic, it is vitally necessary to establish preven-
tive measures to avoid as far as possible the origin of this disease. Therefore, it is 
necessary to carry out well-conducted studies, with appropriate sample size and 
in which the “gold-standard” diagnosis serves to distinguish between cases and 
controls. Moreover, the combined effect of multiple EDCs on endometriosis should 
be addressed. These studies are needed to fully elucidate the potential disrupting 
properties of these PCP-released EDCs in the gynecological tissues. In this way, 
preventive measures could be established, the chemical composition of PCPs could 
be modified by other substances that are not endocrine disruptors, or the use of 
these cosmetics could be reduced as far as possible.
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